Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease. It also develops product candidates, which are in preclinical stage, including ATH-1019 for peripheral nervous system indications; and ATH-1020 for neuropsychiatric conditions. Athira Pharma, Inc. was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. The company was incorporated in 2011 and is headquartered in Bothell, Washington.
Revenue of Athira Pharma, Inc. (ATHA)
Revenue in 2023 (TTM): $
According to Athira Pharma, Inc.'s latest financial reports the company's current revenue (TTM) is $. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Athira Pharma, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $ | $-969,000 | $-116,703,000 | $-117,672,000 | $-117,672,000 |
| 2022 | $ | $-1,048,000 | $-94,591,000 | $-95,639,000 | $-87,262,000 |
| 2021 | $ | $-479,000 | $-54,371,000 | $-54,853,000 | $-54,374,000 |
| 2020 | $ | $-2,000,000 | $-19,012,000 | $-19,955,000 | $-18,634,000 |
| 2019 | $ | $ | $-4,815,000 | $-5,161,000 | $-4,702,000 |
| 2018 | $ | $ | $-79,000 | $-5,097,000 | $-5,097,000 |